Lunch ON 2mg Tablet contains Repaglinide 2mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Repaglinide belongs to the meglitinide class of drugs and functions by stimulating pancreatic beta cells to release insulin, thereby reducing postprandial blood glucose levels. It is particularly effective in controlling blood sugar spikes following meals and is often prescribed when diet and exercise alone are insufficient to achieve glycemic control. The rapid onset and short duration of action of Repaglinide allow for flexible dosing with meals, minimizing the risk of prolonged hypoglycemia. Lunch ON 2mg Tablet should be taken shortly before meals, typically two to four times daily, to optimize post-meal glucose regulation. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or hypersensitivity to Repaglinide. Common adverse effects include hypoglycemia, headache, and gastrointestinal disturbances such as nausea and diarrhea. Caution is advised in patients with hepatic or renal impairment, and dose adjustments may be necessary. Regular monitoring of blood glucose levels is essential to ensure therapeutic efficacy and safety. Lunch ON 2mg Tablet should be used as part of a comprehensive diabetes management plan including diet, exercise, and lifestyle modifications.